Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
Heba Alkhatib(Hebrew University of Jerusalem), Nataly Kravchenko‐Balasha(Hebrew University of Jerusalem), Matthew P. Goetz(Mayo Clinic), Jason E. Conage‐Pough(Massachusetts Institute of Technology), Einat Carmon(Hebrew University of Jerusalem), Sangita Roy Chowdhury(Hebrew University of Jerusalem), Ariel M. Rubinstein(Bar-Ilan University), Judy C. Boughey(Mayo Clinic in Arizona), Ishwar N. Kohale(Amgen (United States)), Liewei Wang(Mayo Clinic), Avital Granit(Hadassah Medical Center), Tamar Peretz-Yablonsky(Hadassah Medical Center), Denen Shian(Hebrew University of Jerusalem), Forest M. White(Center for Cancer Research), Deema Zaid(Hebrew University of Jerusalem), Amir Sonnenblick(Tel Aviv University)
Cited by 12
Related Papers
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
|Nature Biotechnology|2002|1.6k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
|npj Breast Cancer|2019|673